Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy

Michael Frahm, Sebastian Felgner, Dino Kocijancic, Manfred Rohde, Michael Hensel, Iii Roy Curtiss, Marc Erhardt, Siegfried Weiss

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Increasing numbers of cancer cases generate a great urge for new treatment options. Applying bacteria like Salmonella enterica serovar Typhimurium for cancer therapy represents an intensively explored option. These bacteria have been shown not only to colonize solid tumors but also to exhibit an intrinsic antitumor effect. In addition, they could serve as tumortargeting vectors for therapeutic molecules. However, the pathogenic S. Typhimurium strains used for tumor therapy need to be attenuated for safe application. Here, lipopolysaccharide (LPS) deletion mutants (ΔrfaL, ΔrfaG, ΔrfaH, ΔrfaD, ΔrfaP, and ΔmsbB mutants) of Salmonella were investigated for efficiency in tumor therapy. Of such variants, the ΔrfaD and ΔrfaG deep rough mutants exhibited the best tumor specificity and lowest pathogenicity. However, the intrinsic antitumor effect was found to be weak. To overcome this limitation, conditional attenuation was tested by complementing the mutants with an inducible arabinose promoter. The chromosomal integration of the respective LPS biosynthesis genes into the araBAD locus exhibited the best balance of attenuation and therapeutic benefit. Thus, the present study establishes a basis for the development of an applicably cancer therapeutic bacterium.

Original languageEnglish (US)
Article numbere00254-15
Pages (from-to)1-11
Number of pages11
JournalmBio
Volume6
Issue number2
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Salmonella enterica
Bacteria
Neoplasms
Therapeutics
Lipopolysaccharides
Arabinose
Serogroup
Salmonella
Virulence
Genes

ASJC Scopus subject areas

  • Microbiology
  • Virology

Cite this

Frahm, M., Felgner, S., Kocijancic, D., Rohde, M., Hensel, M., Curtiss, I. R., ... Weiss, S. (2015). Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy. mBio, 6(2), 1-11. [e00254-15]. https://doi.org/10.1128/mBio.00254-15

Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy. / Frahm, Michael; Felgner, Sebastian; Kocijancic, Dino; Rohde, Manfred; Hensel, Michael; Curtiss, Iii Roy; Erhardt, Marc; Weiss, Siegfried.

In: mBio, Vol. 6, No. 2, e00254-15, 2015, p. 1-11.

Research output: Contribution to journalArticle

Frahm, M, Felgner, S, Kocijancic, D, Rohde, M, Hensel, M, Curtiss, IR, Erhardt, M & Weiss, S 2015, 'Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy', mBio, vol. 6, no. 2, e00254-15, pp. 1-11. https://doi.org/10.1128/mBio.00254-15
Frahm, Michael ; Felgner, Sebastian ; Kocijancic, Dino ; Rohde, Manfred ; Hensel, Michael ; Curtiss, Iii Roy ; Erhardt, Marc ; Weiss, Siegfried. / Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy. In: mBio. 2015 ; Vol. 6, No. 2. pp. 1-11.
@article{d5f6a9d79e35423abb953128bc44c09c,
title = "Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy",
abstract = "Increasing numbers of cancer cases generate a great urge for new treatment options. Applying bacteria like Salmonella enterica serovar Typhimurium for cancer therapy represents an intensively explored option. These bacteria have been shown not only to colonize solid tumors but also to exhibit an intrinsic antitumor effect. In addition, they could serve as tumortargeting vectors for therapeutic molecules. However, the pathogenic S. Typhimurium strains used for tumor therapy need to be attenuated for safe application. Here, lipopolysaccharide (LPS) deletion mutants (ΔrfaL, ΔrfaG, ΔrfaH, ΔrfaD, ΔrfaP, and ΔmsbB mutants) of Salmonella were investigated for efficiency in tumor therapy. Of such variants, the ΔrfaD and ΔrfaG deep rough mutants exhibited the best tumor specificity and lowest pathogenicity. However, the intrinsic antitumor effect was found to be weak. To overcome this limitation, conditional attenuation was tested by complementing the mutants with an inducible arabinose promoter. The chromosomal integration of the respective LPS biosynthesis genes into the araBAD locus exhibited the best balance of attenuation and therapeutic benefit. Thus, the present study establishes a basis for the development of an applicably cancer therapeutic bacterium.",
author = "Michael Frahm and Sebastian Felgner and Dino Kocijancic and Manfred Rohde and Michael Hensel and Curtiss, {Iii Roy} and Marc Erhardt and Siegfried Weiss",
year = "2015",
doi = "10.1128/mBio.00254-15",
language = "English (US)",
volume = "6",
pages = "1--11",
journal = "mBio",
issn = "2161-2129",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy

AU - Frahm, Michael

AU - Felgner, Sebastian

AU - Kocijancic, Dino

AU - Rohde, Manfred

AU - Hensel, Michael

AU - Curtiss, Iii Roy

AU - Erhardt, Marc

AU - Weiss, Siegfried

PY - 2015

Y1 - 2015

N2 - Increasing numbers of cancer cases generate a great urge for new treatment options. Applying bacteria like Salmonella enterica serovar Typhimurium for cancer therapy represents an intensively explored option. These bacteria have been shown not only to colonize solid tumors but also to exhibit an intrinsic antitumor effect. In addition, they could serve as tumortargeting vectors for therapeutic molecules. However, the pathogenic S. Typhimurium strains used for tumor therapy need to be attenuated for safe application. Here, lipopolysaccharide (LPS) deletion mutants (ΔrfaL, ΔrfaG, ΔrfaH, ΔrfaD, ΔrfaP, and ΔmsbB mutants) of Salmonella were investigated for efficiency in tumor therapy. Of such variants, the ΔrfaD and ΔrfaG deep rough mutants exhibited the best tumor specificity and lowest pathogenicity. However, the intrinsic antitumor effect was found to be weak. To overcome this limitation, conditional attenuation was tested by complementing the mutants with an inducible arabinose promoter. The chromosomal integration of the respective LPS biosynthesis genes into the araBAD locus exhibited the best balance of attenuation and therapeutic benefit. Thus, the present study establishes a basis for the development of an applicably cancer therapeutic bacterium.

AB - Increasing numbers of cancer cases generate a great urge for new treatment options. Applying bacteria like Salmonella enterica serovar Typhimurium for cancer therapy represents an intensively explored option. These bacteria have been shown not only to colonize solid tumors but also to exhibit an intrinsic antitumor effect. In addition, they could serve as tumortargeting vectors for therapeutic molecules. However, the pathogenic S. Typhimurium strains used for tumor therapy need to be attenuated for safe application. Here, lipopolysaccharide (LPS) deletion mutants (ΔrfaL, ΔrfaG, ΔrfaH, ΔrfaD, ΔrfaP, and ΔmsbB mutants) of Salmonella were investigated for efficiency in tumor therapy. Of such variants, the ΔrfaD and ΔrfaG deep rough mutants exhibited the best tumor specificity and lowest pathogenicity. However, the intrinsic antitumor effect was found to be weak. To overcome this limitation, conditional attenuation was tested by complementing the mutants with an inducible arabinose promoter. The chromosomal integration of the respective LPS biosynthesis genes into the araBAD locus exhibited the best balance of attenuation and therapeutic benefit. Thus, the present study establishes a basis for the development of an applicably cancer therapeutic bacterium.

UR - http://www.scopus.com/inward/record.url?scp=84928796820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928796820&partnerID=8YFLogxK

U2 - 10.1128/mBio.00254-15

DO - 10.1128/mBio.00254-15

M3 - Article

VL - 6

SP - 1

EP - 11

JO - mBio

JF - mBio

SN - 2161-2129

IS - 2

M1 - e00254-15

ER -